Abionic developed and tested the PSP sentinel assay for detecting subclinical infections in critical care.
Public source
Publisher name
Public post
Sepsis is the devastating result of a missed infection that can progress rapidly to septic shock, organ failure, and death, claiming 11 million lives worldwide every yeaโฆ
Company
Abionic
Lab-quality results within minutes, at the point-of-care!
- Industry
- Medical Equipment Manufacturing
- Location
- Epalinges, CH
- Company size
- 11โ50 employees
About Abionic
The winner of multiple industry awards, including "Swiss MedTech of the year" in 2023, Abionic is a Swiss MedTech company spun-out of EPFL in 2010 on a vision nanofluidics could transform diagnostics. Our flagship abioSCOPEยฎ, a near-patient rapid diagnostic platform, delivers lab-quality results from a drop of blood within minutes, providing valuable clinical insights and actionable information at the point-of-care.
See moreLatest activity
Latest activity from Abionic
6 signals
Presence & Recognition
Abionic is hosting a webinar on tracking Pancreatic Stone Protein (PSP) to detect subclinical infectious signals in severe trauma and burn cases during Sepsis Awareness Month
Presence & Recognition
Abionic CTO Iwan Mรคrki is briefing attendees at the NATO Medical Innovation Workshop in Budapest on deploying the sentinel biomarker PSP in high-stakes military care.
Presence & Recognition
Abionic will meet the CEO during the upcoming LSX London Investment Showcase.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Vygon UK
Vygon UK published an article bringing together recommendations from global vascular access and infection prevention experts to help clinicians and healthcare organisations make informed decisions about needle free access devices.
Research & Knowledge
DIAMED Medizintechnik GmbH
DIAMED Medizintechnik GmbH published a study showing Plasma-Adsorptions-Perfusion (PAP/Leberpherese) using anion exchange adsorbers in comparison to open albumindialysis (OPAL) for extracorporeal liver support.
Research & Knowledge
Interrad Medical
Interrad Medical published a study conducted at the University of Arkansas for Medical Sciences (UAMS) showing that SecurAcath reduced the risk of Central Line-Associated Bloodstream Infections (CLABSI) by 74% compared to adhesive securement devices.
Research & Knowledge
PercuSense
PercuSense conducted a recently started ICU study where a PercuSense continuous metabolic sensor was placed into a patient six hours after an out-of-hospital cardiac arrest.
Research & Knowledge
Kurin Inc.